• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Foghorn Therapeutics (FHTX)

Common Shares
Sell: $4.53|Buy: $5.00|Change: 0.20 (-4.18%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

Address

100 Binney Street
Suite 610
Cambridge
MA
USA
02142

Telephone

+1 617 586-3100

Website

https://www.foghorntx.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Foghorn Therapeutics Inc Annual Report for 20262027-03-11T00:00:00
Foghorn Therapeutics Inc Fourth Quarter Earnings Results for 20262027-03-11T00:00:00
Foghorn Therapeutics Inc Third Quarter Earnings Results for 20262026-11-05T00:00:00
Foghorn Therapeutics Inc Second Quarter Earnings Results for 20262026-08-05T00:00:00
Foghorn Therapeutics Inc Annual General Meeting for 20262026-06-17T09:00:00
Foghorn Therapeutics Inc First Quarter Earnings Results for 20262026-05-14T00:00:00

Previous key dates

NameKey Date
Foghorn Therapeutics Inc Annual Report for 20252026-03-11T00:00:00
Foghorn Therapeutics Inc Fourth Quarter Earnings Results for 20252026-03-11T00:00:00
TD Cowen 46th Annual Health Care Conference2026-03-03T11:10:00
8(th) Annual Evercore Healthcare Conference2025-12-04T09:10:00
Jefferies 2025 London Healthcare Conference2025-11-19T05:30:00
Stifel 2025 Healthcare Conference2025-11-13T16:00:00
Guggenheim Second Annual Healthcare Innovation Conference2025-11-10T11:00:00
Foghorn Therapeutics Inc Third Quarter Earnings Results for 20252025-11-05T00:00:00
Pipeline Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs2025-10-30T12:00:00
Foghorn Therapeutics Inc Second Quarter Earnings Results for 20252025-08-05T00:00:00
Foghorn Therapeutics Inc Annual General Meeting for 20252025-06-17T09:00:00
Goldman Sachs 46th Annual Global Healthcare Conference 20252025-06-11T10:00:00
Jefferies global healthcare conference 20252025-06-05T15:45:00
Foghorn Therapeutics Inc First Quarter Earnings Results for 20252025-05-14T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.